Login to Your Account

SHANGHAI – Newly minted Zai Lab Ltd., of Shanghai, has made its eagerly awaited debut announcement, obtaining global rights to two Sanofi SA preclinical compounds for chronic respiratory diseases.
A year after its official launch, Curtana Pharmaceuticals Inc. stepped onstage holding a $7.6 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund its lead cancer therapy program, which is targeting the OLIG2 transcription factor (TF) – initially in glioblastoma multiforme (GBM).
Nearly two years after the Buck Institute for Research on Aging partnered with British firm Biotica Technology Ltd. to explore diseases of aging through the creation of Delos Pharmaceuticals Inc., a similar deal is afoot in the area of autoimmune disorders.
More Newco News Headlines

Cast Your Vote

Has biotech’s bubble burst?: